{"id":"https://openalex.org/W45020151","doi":null,"title":"Pimavanserin - a potential first line therapy for Parkinson's disease psychosis","display_name":"Pimavanserin - a potential first line therapy for Parkinson's disease psychosis","publication_year":2009,"publication_date":"2009-04-20","ids":{"openalex":"https://openalex.org/W45020151","mag":"45020151"},"language":"en","primary_location":{"id":"mag:45020151","doi":null,"is_oa":false,"landing_page_url":"http://scnp.org/journal/index.php/SCNP/article/view/20/0","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053715653","display_name":"Uli Hacksell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I125377440","display_name":"Acadia Pharmaceuticals (United States)","ror":"https://ror.org/030bhbq32","country_code":"US","type":"company","lineage":["https://openalex.org/I125377440"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Uli Hacksell","raw_affiliation_strings":["ACADIA PHARMACEUTICALS INC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ACADIA PHARMACEUTICALS INC","institution_ids":["https://openalex.org/I125377440"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012594959","display_name":"Krista McFarland","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Krista McFarland","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104349049","display_name":"Hilde Williams","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hilde Williams","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071264843","display_name":"D BONHAUS","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D BONHAUS","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5003930471","display_name":"Roger Mills","orcid":"https://orcid.org/0000-0002-3993-4180","observed_orcids":["https://orcid.org/0000-0002-3993-4180"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Roger Mills","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3993-4180","affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.00501818,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"2","issue":"1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9560999870300293,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9560999870300293,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.03189999982714653,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.0052999998442828655,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pimavanserin","display_name":"pimavanserin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/parkinson-s-disease-psychosis","display_name":"Parkinson's disease psychosis","score":0.9300000071525574},{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.7509999871253967},{"id":"https://openalex.org/keywords/prepulse-inhibition","display_name":"prepulse inhibition","score":0.8360000252723694},{"id":"https://openalex.org/keywords/amphetamine-response","display_name":"amphetamine response","score":0.7269999980926514},{"id":"https://openalex.org/keywords/dopamine-replacement-therapy","display_name":"dopamine replacement therapy","score":0.8479999899864197},{"id":"https://openalex.org/keywords/unmet-medical-needs","display_name":"unmet medical needs","score":0.6520000100135803}],"concepts":[{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.7457224130630493},{"id":"https://openalex.org/C2779727114","wikidata":"https://www.wikidata.org/wiki/Q170082","display_name":"Psychosis","level":2,"score":0.7018013000488281},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6432912349700928},{"id":"https://openalex.org/C2777193897","wikidata":"https://www.wikidata.org/wiki/Q179452","display_name":"Amphetamine","level":3,"score":0.4588056802749634},{"id":"https://openalex.org/C89951826","wikidata":"https://www.wikidata.org/wiki/Q1671731","display_name":"Inverse agonist","level":4,"score":0.4474473297595978},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.4447779059410095},{"id":"https://openalex.org/C141421786","wikidata":"https://www.wikidata.org/wiki/Q1128897","display_name":"Prepulse inhibition","level":3,"score":0.4407097399234772},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.44046738743782043},{"id":"https://openalex.org/C44208683","wikidata":"https://www.wikidata.org/wiki/Q15335165","display_name":"Dopamine receptor D2","level":3,"score":0.42710500955581665},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.40077272057533264},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.38532429933547974},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.37957173585891724},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.2819528579711914},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.27931272983551025},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.25001922249794006},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.18000516295433044}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:45020151","doi":null,"is_oa":false,"landing_page_url":"http://scnp.org/journal/index.php/SCNP/article/view/20/0","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9907000064849854,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7052005567","https://openalex.org/W2061320396","https://openalex.org/W4229508902","https://openalex.org/W2747316860","https://openalex.org/W1967630951","https://openalex.org/W4254614969","https://openalex.org/W4378716599","https://openalex.org/W2047004456","https://openalex.org/W2980209530","https://openalex.org/W2333444689"],"abstract_inverted_index":{"Pimavanserin":[0],"(ACP-103)":[1],"is":[2,53],"a":[3,92,175,195],"novel":[4],"and":[5,124],"selective":[6],"5-HT":[7],"2A":[8],"inverse":[9],"agonist":[10],"currently":[11,54,115],"in":[12,62,91,112,121,130,141,199,201],"Phase":[13,177],"III":[14],"development":[15],"for":[16,27,60,75,159,167],"Parkinson\u2019s":[17,49],"disease":[18,50],"psychosis":[19,200],"(PDP).":[20],"Most":[21],"antipsychotic":[22,156,163],"drugs":[23],"cannot":[24],"be":[25,152],"used":[26,42],"this":[28,76],"indication":[29,77],"because":[30],"their":[31],"prominent":[32],"dopamine":[33,39],"receptor":[34],"blocking":[35],"potency":[36],"counteracts":[37],"the":[38,45,63,66,69,208],"replacement":[40],"therapy":[41,58,158],"to":[43,81,88,114,128],"alleviate":[44],"motor":[46,169,190],"symptoms":[47,191],"of":[48,83,94,98,133,184,192],"(PD).":[51],"There":[52],"no":[55],"first":[56],"line":[57],"approved":[59],"PDP":[61,134,160,204],"EU":[64],"or":[65],"USA":[67,215],"despite":[68],"well":[70],"established":[71,95],"unmet":[72],"medical":[73],"need":[74],"which":[78,147,180],"afflicts":[79],"up":[80],"40%":[82],"PD":[84,193],"patients.":[85],"In":[86],"addition":[87],"demonstrating":[89],"activity":[90],"variety":[93],"animal":[96],"models":[97,132],"schizophrenia":[99],"(JPET,":[100],"317":[101],",":[102],"910-918,":[103],"2006":[104],"),":[105],"we":[106],"have":[107],"now":[108],"shown":[109],"that":[110,149,182,186],"pimavanserin,":[111],"contrast":[113],"marketed":[116],"antipsychotics,":[117],"potentially":[118],"normalizes":[119],"deficits":[120],"prepulse":[122],"inhibition":[123],"augmented":[125],"behavioral":[126],"responses":[127],"amphetamine":[129],"rodent":[131],"while":[135,165],"not":[136,188],"counteracting":[137],"L-DOPA":[138],"induced":[139],"turning":[140],"unilaterally":[142],"lesioned":[143],"rodents.":[144],"These":[145],"data,":[146],"indicate":[148],"pimavanserin":[150,185],"can":[151],"differentiated":[153],"from":[154],"current":[155],"off-label":[157],"by":[161,174,207],"providing":[162],"activity,":[164],"allowing":[166],"optimal":[168],"control,":[170],"are":[171],"further":[172],"supported":[173],"proof-of-concept":[176],"II":[178],"study":[179],"demonstrated":[181],"doses":[183],"do":[187],"worsen":[189],"provide":[194],"clinically":[196],"meaningful":[197],"reduction":[198],"patients":[202],"with":[203],"as":[205],"measured":[206],"SAPS.":[209],"ACADIA":[210],"Pharmaceuticals":[211],"Inc.,":[212],"San":[213],"Diego,":[214]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}